Author:

Keywords:

CD36, lipids, atherosclerosis, Science & Technology, Multidisciplinary Sciences, Science & Technology - Other Topics, CHAIN FATTY-ACIDS, SCAVENGER RECEPTOR CD36, LOW-DENSITY-LIPOPROTEIN, ADIPOCYTE MEMBRANE-PROTEIN, INSULIN SENSITIVITY, OXIDIZED LDL, CHOLESTEROL UPTAKE, MACROPHAGE, MICE, DEFICIENCY, Animals, Atherosclerosis, Benzimidazoles, CD36 Antigens, Cell Line, Diabetes Complications, Disease Models, Animal, Dyslipidemias, Humans, Hypertriglyceridemia, Insulin Resistance, Male, Mice, Postprandial Period, Rats, Rats, Wistar, Thiophenes, General Science & Technology

Abstract:

CD36 is recognized as a lipid and fatty acid receptor and plays an important role in the metabolic syndrome and associated cardiac events. The pleiotropic activity and the multiple molecular associations of this scavenger receptor with membrane associated molecules in different cells and tissues have however questioned its potential as a therapeutic target. The present study shows that it is possible to identify low molecular weight chemicals that can block the CD36 binding and uptake functions. These inhibitors were able to reduce arterial lipid deposition, fatty acid intestinal transit, plasma concentration of triglycerides and glucose, to improve insulin sensitivity, glucose tolerance and to reduce the plasma concentration of HbAc1 in different and independent rodent models. Correlation between the anti-CD36 activity of these inhibitors and the known pathophysiological activity of this scavenger receptor in the development of atherosclerosis and diabetes were observed at pharmacological doses. Thus, CD36 might represent an attractive therapeutic target.